ProKidney Corp. Class A (PROK)

ProKidney Corp.'s stock experienced significant volatility in the past six months. In July 2025, the stock surged due to promising FDA designations and positive Phase 2 REGEN-007 trial results. The company completed its domestication to Delaware on July 1, 2025. However, the stock plummeted in mid-July 2025 following a downgrade from BofA Securities due to lowered sales expectations. Insider selling occurred in July and November 2025. ProKidney reported its third-quarter 2025 financial results and presented full results from the Phase 2 REGEN-007 trial in November 2025. As of early January 2026, the stock has shown some fluctuations, with a slight decrease in price over recent trading days.

Traditional demand seasonality is not applicable to ProKidney Corp. as a clinical-stage biotechnology company. The demand for its therapy is driven by the progress and outcomes of its clinical studies, regulatory milestones, and the prevalence of chronic kidney disease and type 2 diabetes. The company's focus is on advancing its cell therapy through trials and towards potential commercialization, at which point demand would be influenced by medical need and market access rather than seasonal patterns.

ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases. Their primary product, rilparencel (REACT®), is in Phase 3 and Phase 2 clinical trials, showing potential in preserving kidney function for patients with advanced CKD and type 2 diabetes. Rilparencel has received RMAT designation from the FDA, and a cryopreserved version is also under development.

ProKidney Corp. is headquartered in Winston-Salem, North Carolina, where its operations, manufacturing, research and development, and process development laboratories are located. They also have an office in Boston, Massachusetts. In June 2023, ProKidney purchased a 210,000 square foot facility in Greensboro, North Carolina, to support future commercial manufacturing needs for REACT®.

ProKidney's brand reputation has been influenced by its clinical trial progress and market perception. Positive results from the Phase 2 REGEN-007 trial and the RMAT designation from the FDA boosted the company's reputation. The successful domestication to Delaware could also be viewed positively. However, the stock downgrade by BofA Securities and insider selling had a negative impact on investor confidence. Overall, the company's reputation is closely tied to the success of its clinical trials and regulatory approvals.

ProKidney Corp. has a significant number of institutional owners and shareholders. As of late 2025, there were over 100 institutional owners holding tens of millions of shares, including Suvretta Capital Management, Morgan Stanley, and Vanguard Group Inc. Insider ownership stands at approximately 17.81%. There have been insider purchases over the last year, but also notable insider selling in the past three to twelve months.